Medications can profoundly influence the musculoskeletal system, affecting bone density, tendon integrity, cartilage health, fracture risk, and postoperative recovery. For orthopedic surgeons, sports medicine physicians, physical therapists, and primary care providers, understanding these effects is essential for optimizing patient outcomes and preventing avoidable complications.
This article reviews the orthopedic implications of five commonly prescribed medication classes and hormones: fluoroquinolones, corticosteroids, testosterone, estrogen, and progesterone.
Fluoroquinolones, including ciprofloxacin, levofloxacin, and moxifloxacin, are broad-spectrum antibiotics frequently used to treat respiratory, urinary, and gastrointestinal infections. Despite their effectiveness, they have become well known for their adverse effects on connective tissue.
The most clinically significant orthopedic complication associated with fluoroquinolones is tendinopathy, particularly involving the Achilles tendon. Patients may develop:
Symptoms can occur within days of starting therapy but may also develop weeks or months after discontinuation.
Several mechanisms have been proposed:
These effects weaken tendon structure and impair healing capacity.
Risk is particularly elevated in:
Clinicians should maintain a high index of suspicion when evaluating new tendon pain in patients with recent fluoroquinolone exposure. Early discontinuation of the antibiotic, activity modification, and orthopedic assessment may help prevent rupture.
Corticosteroids remain indispensable for treating inflammatory and autoimmune conditions. However, chronic exposure can have substantial orthopedic repercussions.
Glucocorticoid-induced osteoporosis is among the most common forms of secondary osteoporosis.
Corticosteroids:
As a result, patients experience rapid bone loss, particularly within the first year of treatment.
Common fracture sites include:
Avascular necrosis (osteonecrosis) is another serious complication.
The femoral head is most frequently affected, although the shoulder, knee, and ankle may also be involved.
Patients often present with:
Advanced cases may require joint replacement.
Both systemic and local corticosteroid exposure can impair tendon structure by:
Achilles, patellar, and rotator cuff tendons may be particularly vulnerable.
Chronic corticosteroid use may contribute to:
Preoperative assessment should include evaluation of steroid exposure and bone health.
Testosterone exerts substantial anabolic effects throughout the musculoskeletal system.
Physiologic testosterone supports:
Hypogonadal men often demonstrate decreased bone density and increased rates of osteopenia and osteoporosis.
Testosterone replacement therapy can improve bone mineral density, particularly in the lumbar spine and hip.
Testosterone promotes:
These effects may improve functional recovery following injury or surgery in appropriately selected patients.
The relationship between testosterone and tendon health is complex.
While increased muscle strength may improve performance, rapid gains in muscle force can outpace tendon adaptation, potentially increasing tendon loading. Some studies suggest an association between exogenous anabolic-androgenic steroid use and tendon injury, particularly when supraphysiologic doses are employed.
Reported injuries include:
Importantly, these risks are primarily associated with anabolic steroid abuse rather than medically supervised testosterone replacement.
Appropriate testosterone replacement may improve musculoskeletal health in hypogonadal individuals. However, clinicians should remain vigilant regarding tendon injuries in patients using anabolic agents or engaging in aggressive strength training programs.
Estrogen is one of the most important regulators of bone metabolism.
Estrogen suppresses osteoclast-mediated bone resorption and helps maintain bone density.
When estrogen levels decline, particularly during menopause:
This process contributes significantly to postmenopausal osteoporosis.
Numerous studies have demonstrated that estrogen replacement can:
The decision to initiate hormone therapy must balance skeletal benefits against cardiovascular, oncologic, and thromboembolic considerations.
Estrogen influences:
Research suggests that fluctuations in estrogen levels may affect injury patterns, particularly among female athletes.
Some studies have reported associations between hormonal changes and increased risk of anterior cruciate ligament (ACL) injury, although the exact relationship remains under investigation.
Emerging evidence suggests estrogen may have protective effects on articular cartilage and may influence osteoarthritis progression. However, definitive conclusions remain elusive.
Compared with estrogen and testosterone, progesterone has received less orthopedic attention. Nevertheless, it appears to play meaningful roles in musculoskeletal physiology.
Progesterone may support bone formation by stimulating osteoblast activity.
Although estrogen remains the dominant hormone in preserving bone mass, progesterone may contribute synergistically to skeletal health.
Progesterone receptors are present within connective tissues, suggesting potential effects on:
Hormonal fluctuations during the menstrual cycle may influence ligament properties and injury susceptibility.
Elevated progesterone levels during pregnancy contribute to physiologic changes in connective tissue.
These adaptations may increase:
While beneficial for childbirth, they can alter biomechanics and potentially increase injury risk.
The independent orthopedic effects of progesterone remain less clearly defined than those of estrogen or testosterone. Ongoing research continues to explore its role in bone health, tendon function, and injury risk.
Several commonly prescribed medications and endogenous hormones significantly influence musculoskeletal health.
Recognizing these relationships allows clinicians to better assess risk, guide treatment decisions, and optimize outcomes for patients across the orthopedic spectrum.